116 related articles for article (PubMed ID: 19639286)
1. A3 adenosine receptor: pharmacology and role in disease.
Borea PA; Gessi S; Bar-Yehuda S; Fishman P
Handb Exp Pharmacol; 2009; (193):297-327. PubMed ID: 19639286
[TBL] [Abstract][Full Text] [Related]
2. The A3 adenosine receptor: an enigmatic player in cell biology.
Gessi S; Merighi S; Varani K; Leung E; Mac Lennan S; Borea PA
Pharmacol Ther; 2008 Jan; 117(1):123-40. PubMed ID: 18029023
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of A2 and A3 adenosine receptor: a review of novel patented ligands.
Federico S; Spalluto G
Expert Opin Ther Pat; 2012 Apr; 22(4):369-90. PubMed ID: 22435652
[TBL] [Abstract][Full Text] [Related]
4. A3 adenosine receptor-mediated protection of the ischemic heart.
Headrick JP; Peart J
Vascul Pharmacol; 2005; 42(5-6):271-9. PubMed ID: 15922260
[TBL] [Abstract][Full Text] [Related]
5. A1 adenosine receptor antagonists, agonists, and allosteric enhancers.
Kiesman WF; Elzein E; Zablocki J
Handb Exp Pharmacol; 2009; (193):25-58. PubMed ID: 19639278
[TBL] [Abstract][Full Text] [Related]
6. The A3 adenosine receptor: history and perspectives.
Borea PA; Varani K; Vincenzi F; Baraldi PG; Tabrizi MA; Merighi S; Gessi S
Pharmacol Rev; 2015; 67(1):74-102. PubMed ID: 25387804
[TBL] [Abstract][Full Text] [Related]
7. The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.
Cheong SL; Federico S; Venkatesan G; Mandel AL; Shao YM; Moro S; Spalluto G; Pastorin G
Med Res Rev; 2013 Mar; 33(2):235-335. PubMed ID: 22095687
[TBL] [Abstract][Full Text] [Related]
8. Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice.
Björklund O; Halldner-Henriksson L; Yang J; Eriksson TM; Jacobson MA; Daré E; Fredholm BB
Physiol Behav; 2008 Dec; 95(5):668-76. PubMed ID: 18930070
[TBL] [Abstract][Full Text] [Related]
9. Receptor-driven identification of novel human A₃ adenosine receptor antagonists as potential therapeutic agents.
Paoletta S; Federico S; Spalluto G; Moro S
Methods Enzymol; 2010; 485():225-44. PubMed ID: 21050920
[TBL] [Abstract][Full Text] [Related]
10. Purinergic receptors in gastrointestinal inflammation.
Kolachala VL; Bajaj R; Chalasani M; Sitaraman SV
Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G401-10. PubMed ID: 18063703
[TBL] [Abstract][Full Text] [Related]
11. Recent developments in adenosine A2A receptor ligands.
Cristalli G; Müller CE; Volpini R
Handb Exp Pharmacol; 2009; (193):59-98. PubMed ID: 19639279
[TBL] [Abstract][Full Text] [Related]
12. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment.
Bar-Yehuda S; Rath-Wolfson L; Del Valle L; Ochaion A; Cohen S; Patoka R; Zozulya G; Barer F; Atar E; Piña-Oviedo S; Perez-Liz G; Castel D; Fishman P
Arthritis Rheum; 2009 Oct; 60(10):3061-71. PubMed ID: 19790055
[TBL] [Abstract][Full Text] [Related]
13. A1 adenosine receptor: role in diabetes and obesity.
Dhalla AK; Chisholm JW; Reaven GM; Belardinelli L
Handb Exp Pharmacol; 2009; (193):271-95. PubMed ID: 19639285
[TBL] [Abstract][Full Text] [Related]
14. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration.
Stone TW; Ceruti S; Abbracchio MP
Handb Exp Pharmacol; 2009; (193):535-87. PubMed ID: 19639293
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in A2B adenosine receptor ligands.
Kalla RV; Zablocki J; Tabrizi MA; Baraldi PG
Handb Exp Pharmacol; 2009; (193):99-122. PubMed ID: 19639280
[TBL] [Abstract][Full Text] [Related]
16. Molecular docking study of A(3) adenosine receptor antagonists and pharmacophore-based drug design.
Wei J; Li H; Qu W; Gao Q
Neurochem Int; 2009 Dec; 55(7):637-42. PubMed ID: 19540293
[TBL] [Abstract][Full Text] [Related]
17. The role of nitric oxide in A3 adenosine receptor-mediated cardioprotection.
Hussain A; Karjian P; Maddock H
Auton Autacoid Pharmacol; 2009 Jul; 29(3):97-104. PubMed ID: 19566749
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and therapeutic applications of A3 receptor subtype.
Fishman P; Bar-Yehuda S
Curr Top Med Chem; 2003; 3(4):463-9. PubMed ID: 12570762
[TBL] [Abstract][Full Text] [Related]
19. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.
Fishman P; Cohen S
Clin Rheumatol; 2016 Sep; 35(9):2359-62. PubMed ID: 26886128
[TBL] [Abstract][Full Text] [Related]
20. Adenosine receptor modulation: potential implications in veterinary medicine.
Dip RG
Vet J; 2009 Jan; 179(1):38-49. PubMed ID: 17904398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
